Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.43 |
| ▸ | GAPDH | P04406 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24941146 | 1.00 | USP2 (0.52) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL10865013 | 1.00 | USP2 (0.52) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL7213369 | 1.00 | USP2 (0.52) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL10864836 | 1.00 | USP2 (0.52) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL14553315 | 0.89 | POLB (0.44) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL20927140 | 0.87 | USP2 (0.52) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL21650361 | 0.86 | USP2 (0.51) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL21650362 | 0.84 | USP2 (0.49) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL11318512 | 0.83 | ALDH1A1 (0.50) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL21650360 | 0.82 | USP2 (0.50) | USP2POLBMEN1KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0171171-B1 | A PROCESS FOR PREPARING 2-BETA-D-RIBOFURANOSYLSELENAZOLE-4-CARBOXAMIDE | WARNER-LAMBERT COMPANY (US) | 1990-04-25 | — | — | EP | claimed |
| US-4619996-A | Process for preparing 2-β-D-ribofuranosylselenazole-4-carboxamide | WARNER-LAMBERT COMPANY (US) | 1986-10-28 | — | — | US | claimed |
| EP-0171171-A1 | A process for preparing 2-beta-D-ribofuranosylselenazole-4-carboxamide | WARNER-LAMBERT COMPANY (US) | 1986-02-12 | — | — | EP | claimed |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2023-09-28 | — | — | US | disclosed |
| US-11667663-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | BIOARDIS LLC | 2023-02-02 | — | — | US | disclosed |
| EP-4055026-A1 | COMPOUNDS AS CD73 INHIBITORS | Bioardis LLC (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114945578-A | Compounds as CD73 inhibitors | 博奥阿迪斯生物科技公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
| EP-0171171-A1 | A process for preparing 2-beta-D-ribofuranosylselenazole-4-carboxamide | WARNER-LAMBERT COMPANY (US) | 1986-02-12 | — | — | EP | disclosed |
| EP-0171171-A1 | A process for preparing 2-beta-D-ribofuranosylselenazole-4-carboxamide | WARNER-LAMBERT COMPANY (US) | 1986-02-12 | — | — | EP | disclosed |
| US-4544741-A | Azole dinucleotide compounds and methods for their production | BRIGHAM YOUNG UNIVERSITY, PROVO, UT., A NONPROFIT CORP. OF UT | 1985-10-01 | — | — | US | disclosed |
| US-4531001-A | 2-β-D-ribofuranosylselenazole-4-carboxamide compounds | BRIGHAM YOUNG UNIVERSITY (US) | 1985-07-23 | — | — | US | disclosed |
| US-4451648-A | VIRICIDE BY MULTI-STEP PROCESS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1984-05-29 | — | — | US | disclosed |
| EP-0090405-A1 | Novel azole dinucleotide compounds and methods for their production | BRIGHAM YOUNG UNIVERSITY (US) | 1983-10-05 | — | — | EP | disclosed |
| EP-0089678-A1 | Novel 2-beta-D-ribofuranosylselenazole-4-carboxamide compounds and methods for their production | BRIGHAM YOUNG UNIVERSITY (US) | 1983-09-28 | — | — | EP | disclosed |
| EP-0072977-A1 | Process for the production of 2-beta-D-ribofuranosylthiazole-4-carboxamide | Starks Associates, Incorporated (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0072977-A1 | Process for the production of 2-beta-D-ribofuranosylthiazole-4-carboxamide | Starks Associates, Incorporated (US) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | USP2 4174/4885POLB 1585/4885MEN1 2427/4885 |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | RAN, RANBP1, GDI2 | USP2 4401/4885POLB 1318/4885MEN1 1886/4885 |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | USP2 4165/4885POLB 31/4885MEN1 1929/4885 |
| US-11667663-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, DUT | USP2 3819/4885POLB 40/4885MEN1 2234/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | USP2 4165/4885POLB 31/4885MEN1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.